[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100629392":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":26,"responsibleParty":41,"collaborators":26,"id":43,"slug":26,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":26,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":50,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":26,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":67,"whyStopped":26,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":26},{"fullName":5,"class":6},"Sultan Qaboos University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Tranexamic acid","EXPERIMENTAL","Women who receive intravenous, Tranexamic acid for prophylaxis of postpartum hemorrhage",[13],"Drug: tranexamic acid (1 g diluted in 100 mL of 0.9% saline",{"label":15,"type":16,"description":17,"interventionNames":18},"Normal Saline","PLACEBO_COMPARATOR","Women who will receive 0.9% saline, intravenous, volume matched",[19],"Drug: Normal (0.9%) saline",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","tranexamic acid (1 g diluted in 100 mL of 0.9% saline","This intervention is currently used for treatment of postpartum hemorrhage and not a routine prophylaxis",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Normal (0.9%) saline","Intravenous volume matched normal 0.9% saline",[15],[32,37],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Vaidyanathan Gowri, Doctor","CONTACT","+968 99416909","gowri@squ.edu.om",{"name":38,"role":34,"phone":39,"phoneExt":26,"email":40},"Meenakshi R Menon, Doctor","+968 91378237","m.ram@squ.edu.om",{"type":42,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100629392",false,"NCT07474077","Investigating the Efficacy of Tranexamic Acid as a Prophylactic Agent in Reducing Postpartum Hemorrhage Among Patients Undergoing Cesarean Section in SQUH","PROPHYLACTIC TRANEXAMIC ACID IN REDUCING POSTPARTUM HEMORRHAGE IN CESAREAN SECTIONS","Inclusion Criteria:\n\nPregnant woman with risk factors for postpartum haemorrhage undergoing elective and emergency caesarean section in SQUH.\n\n* Previous Caesarean Section\n* Multiple pregnancy,\n* Polyhydramnios,\n* Fetal macrosomia (BW \\>4kg),\n* Anemia\n* Booking BMI\\>30\n* Previous history of postpartum hemorrhage\n* Fibroids,\n* Adenomyosis,\n* Placenta previa (non- accreta),\n* Chorioamnionitis.\n\nExclusion Criteria: Woman with conditions like\n\n* Placenta accreta spectrum,\n* Contraindications to tranexamic acid (e.g., hypersensitivity to tranexamic acid), -History of seizure disorders,\n* Kidney disease,\n* Thromboembolic disease,\n* Medical conditions or treatments associated with a high risk of thrombosis",true,"FEMALE","18 Years","45 Years",{"count":54,"type":55},88,"ESTIMATED","INTERVENTIONAL",[58],"PHASE3","Investigating the efficacy of tranexamic acid (TXA) as a prophylactic agent in reducing postpartum haemorrhage (PPH) among patients undergoing cesarean section (CS) in SQUH: a prospective randomized controlled trial.",[61],"Post Partum Haemorrhage",[63,64,65,66],"Post partum haemorrhage","tranexamic acid","Caesarean section","Pregnancy","NOT_YET_RECRUITING","2026-03-26",{"date":70,"type":71},"2026-04-01","ACTUAL",{"date":73,"type":55},"2026-05-01",{"date":75,"type":55},"2028-03-31",{"name":5,"class":6}]